Compare · ABT vs ZYNE
ABT vs ZYNE
Side-by-side comparison of Abbott Laboratories (ABT) and Zynerba Pharmaceuticals Inc. (ZYNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ZYNE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $179.90B.
- ABT has hit the wire 11 times in the past 4 weeks while ZYNE has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 0 for ZYNE).
- Company
- Abbott Laboratories
- Zynerba Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $179.90B
- -
- 1M return
- +3.34%
- -
- 1Y return
- -16.14%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Zynerba Pharmaceuticals Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Latest ABT
- Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis
- Abbott Labs upgraded by Leerink Partners with a new price target
- Abbott Laboratories filed SEC Form 8-K: Leadership Update
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
Latest ZYNE
- SEC Form SC 13G/A filed by Zynerba Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Zynerba Pharmaceuticals Inc.
- SEC Form EFFECT filed by Zynerba Pharmaceuticals Inc.
- Jones Kenneth T was granted 30,000 shares, closing all direct ownership in the company (SEC Form 4)
- Stephenson Pamela closing all direct ownership in the company (SEC Form 4)
- Fickenscher James E was granted 170,000 shares, closing all direct ownership in the company (SEC Form 4)
- Sebree Terri B was granted 170,000 shares, closing all direct ownership in the company (SEC Form 4)
- Federici William J closing all direct ownership in the company (SEC Form 4)
- Rosenberger Brian was granted 120,000 shares, closing all direct ownership in the company (SEC Form 4)
- Cooper Warren D closing all direct ownership in the company (SEC Form 4)